Search Legislation

The Genetically Modified Organisms (Deliberate Release) (Scotland) Regulations 2002

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening OptionsExpand opening options

Changes over time for: Section 15

 Help about opening options

Changes to legislation:

There are currently no known outstanding effects for the The Genetically Modified Organisms (Deliberate Release) (Scotland) Regulations 2002, Section 15. Help about Changes to Legislation

Exempt activitiesS

15.[F1(1)] The cases and circumstances prescribed for the purposes of [F2section] 111(7) of the Act in which persons are exempt from the requirements of F3... section 111(1)(a) of the Act (to obtain consent) F4... insofar as [F5it relates] to marketing genetically modified organisms, are all cases and circumstances in which–

(a)an approved product [F6, which is permitted to be marketed in Scotland in pursuance of an authorisation under the Food and Feed Regulation,] is marketed for a use for which it has approval [F7and in accordance with the limitations [F8, conditions and restrictions] to which [F9that use of the] product is subject];

[F10(aa)a pre-exit approved product is marketed during the relevant period—

(i)for a use (other than cultivation in Scotland) for which it had marketing consent in accordance with the Deliberate Release Directive or the 1990 Directive immediately before exit day and for which it continues to have consent for that use in Scotland, and

(ii)in accordance with the limitations and conditions to which that use of the product was subject immediately before exit day, as may be modified by virtue of these Regulations or the Act,]

(b)genetically modified micro-organisms are made available for activities regulated under [F11the Genetically Modified Organisms (Contained Use) Regulations 2014] (including culture collections);

F12(c). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(d)genetically modified organisms are made available to be used exclusively for deliberate releases complying with the requirements laid down in Part II; [F13and]

[F14(e)a genetically modified organism is marketed which is, or is contained in, a medicinal product authorised under—

(i)the Human Medicines Regulations 2012, or

(ii)the Veterinary Medicines Regulations 2013.]

F15(f). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F16(g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[F17(2) For the purposes of paragraph (1), “the relevant period”, in relation to a pre-exit approved product, means the period beginning with exit day and ending with the day which immediately precedes the day on which the consent concerned ceases to be valid.]

Textual Amendments

Back to top

Options/Help